Share on StockTwits

Bio-Reference Laboratories (NASDAQ:BRLI) was downgraded by stock analysts at Bank of America to an “underperform” rating in a report issued on Thursday.

Bio-Reference Laboratories (NASDAQ:BRLI) traded down 8.77% during mid-day trading on Thursday, hitting $29.74. The stock had a trading volume of 287,020 shares. Bio-Reference Laboratories has a 52 week low of $24.13 and a 52 week high of $37.97. The stock’s 50-day moving average is $31.41 and its 200-day moving average is $28.45. The company has a market cap of $824.3 million and a P/E ratio of 23.29.

Bio-Reference Laboratories (NASDAQ:BRLI) last released its earnings data on Wednesday, August 27th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.02. The company had revenue of $222.10 million for the quarter, compared to the consensus estimate of $210.44 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. Analysts expect that Bio-Reference Laboratories will post $1.65 EPS for the current fiscal year.

Bio-Reference Laboratories, Inc (NASDAQ:BRLI) is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.